Petlife Pharmaceuticals's Days Sales Outstanding for the
three
months ended in Feb. 2018 was .
Petlife Pharmaceuticals's Days Inventory for the
three
months ended in Feb. 2018 was 0.
Petlife Pharmaceuticals's Days Payable for the
three
months ended in Feb. 2018 was 0.
Therefore, Petlife Pharmaceuticals's Cash Conversion Cycle (CCC) for the
three
months ended in Feb. 2018 was 0.00.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Petlife Pharmaceuticals Cash Conversion Cycle Related Terms
Petlife Pharmaceuticals Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Petlife Pharmaceuticals's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTLF vs PCYN, YBAO, BKIT: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petlife Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petlife Pharmaceuticals Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petlife Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Petlife Pharmaceuticals's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Petlife Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Aug. 2017 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petlife Pharmaceuticals (PTLF) has a Cash Conversion Cycle of 0.00 as of Feb. 2018. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' Cash Conversion Cycle too high?
Petlife Pharmaceuticals' current Cash Conversion Cycle is 0.00.
How does Petlife Pharmaceuticals' Cash Conversion Cycle compare to PCYN and YBAO?
Petlife Pharmaceuticals' Cash Conversion Cycle of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Petlife Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petlife Pharmaceuticals's current Cash Conversion Cycle is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current Cash Conversion Cycle of 0.00. The current Cash Conversion Cycle is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current Cash Conversion Cycle is 0.00 as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTLF has been successfully added to your 